Literature DB >> 20628345

Hepatocellular carcinoma: A global view.

Ju Dong Yang1, Lewis R Roberts.   

Abstract

Hepatocellular carcinoma (HCC) is a global health problem, although developing countries are disproportionally affected: over 80% of HCCs occur in such regions. About three-quarters of HCCs are attributed to chronic HBV and HCV infections. In areas endemic for HCV and HBV, viral transmission occurs at an early age, and infected individuals develop HCC in mid-adulthood. As these are their most productive years of life, HCC accounts for a substantial burden on the health-care system and drain of productive capacity in the low-income and middle-income countries most affected by HCV and HBV infections. Environments with disparate resource levels require different strategies for the optimal management of HCC. In high-resource environments, guidelines from the American Association for the Study of Liver Diseases or European Association for the Study of the Liver should be applied. In intermediate-resource or low-resource environments, the fundamental focus should be on primary prevention of HCC, through universal HBV vaccination, taking appropriate precautions and antiviral treatments. In intermediate-resource and low-resource environments, the infrastructure and capacity for abdominal ultrasonography, percutaneous ethanol injection, radiofrequency ablation and surgical resection should be established. Programs to provide targeted therapy at low cost, similar to the approach used for HIV therapy in the developing world, should be pursued.

Entities:  

Mesh:

Year:  2010        PMID: 20628345      PMCID: PMC3926946          DOI: 10.1038/nrgastro.2010.100

Source DB:  PubMed          Journal:  Nat Rev Gastroenterol Hepatol        ISSN: 1759-5045            Impact factor:   46.802


  101 in total

Review 1.  Current strategy for staging and treatment: the BCLC update and future prospects.

Authors:  Alejandro Forner; María E Reig; Carlos Rodriguez de Lope; Jordi Bruix
Journal:  Semin Liver Dis       Date:  2010-02-19       Impact factor: 6.115

2.  Prevalence of overweight and obesity in the United States, 1999-2004.

Authors:  Cynthia L Ogden; Margaret D Carroll; Lester R Curtin; Margaret A McDowell; Carolyn J Tabak; Katherine M Flegal
Journal:  JAMA       Date:  2006-04-05       Impact factor: 56.272

3.  A prospective study on downstaging of hepatocellular carcinoma prior to liver transplantation.

Authors:  Francis Y Yao; Ryutaro Hirose; Jeanne M LaBerge; Timothy J Davern; Nathan M Bass; Robert K Kerlan; Raphael Merriman; Sandy Feng; Chris E Freise; Nancy L Ascher; John P Roberts
Journal:  Liver Transpl       Date:  2005-12       Impact factor: 5.799

4.  Prognosis of hepatocellular carcinoma: the BCLC staging classification.

Authors:  J M Llovet; C Brú; J Bruix
Journal:  Semin Liver Dis       Date:  1999       Impact factor: 6.115

5.  Radiofrequency ablation improves prognosis compared with ethanol injection for hepatocellular carcinoma < or =4 cm.

Authors:  Shi-Ming Lin; Chun-Jung Lin; Chen-Chun Lin; Chao-Wei Hsu; Yi-Cheng Chen
Journal:  Gastroenterology       Date:  2004-12       Impact factor: 22.682

6.  Antibody to hepatitis B core antigen and risk for hepatitis C-related hepatocellular carcinoma: a prospective study.

Authors:  Kazuki Ikeda; Hiroyuki Marusawa; Yukio Osaki; Takefumi Nakamura; Naoto Kitajima; Yukitaka Yamashita; Masatoshi Kudo; Tosiya Sato; Tsutomu Chiba
Journal:  Ann Intern Med       Date:  2007-05-01       Impact factor: 25.391

7.  The declining risk of post-transfusion hepatitis C virus infection.

Authors:  J G Donahue; A Muñoz; P M Ness; D E Brown; D H Yawn; H A McAllister; B A Reitz; K E Nelson
Journal:  N Engl J Med       Date:  1992-08-06       Impact factor: 91.245

8.  Alpha-fetoprotein, des-gamma carboxyprothrombin, and lectin-bound alpha-fetoprotein in early hepatocellular carcinoma.

Authors:  Jorge A Marrero; Ziding Feng; Yinghui Wang; Mindie H Nguyen; Alex S Befeler; Lewis R Roberts; K Rajender Reddy; Denise Harnois; Josep M Llovet; Daniel Normolle; Jackie Dalhgren; David Chia; Anna S Lok; Paul D Wagner; Sudhir Srivastava; Myron Schwartz
Journal:  Gastroenterology       Date:  2009-04-09       Impact factor: 22.682

9.  A follow-up study of urinary markers of aflatoxin exposure and liver cancer risk in Shanghai, People's Republic of China.

Authors:  G S Qian; R K Ross; M C Yu; J M Yuan; Y T Gao; B E Henderson; G N Wogan; J D Groopman
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  1994 Jan-Feb       Impact factor: 4.254

10.  Hepatic resection of hepatocellular carcinoma in patients with cirrhosis: Model of End-Stage Liver Disease (MELD) score predicts perioperative mortality.

Authors:  Swee H Teh; John Christein; John Donohue; Florencia Que; Michael Kendrick; Michael Farnell; Stephen Cha; Patrick Kamath; Raymond Kim; David M Nagorney
Journal:  J Gastrointest Surg       Date:  2005-12       Impact factor: 3.267

View more
  519 in total

1.  Hepatitis C virus-induced cancer stem cell-like signatures in cell culture and murine tumor xenografts.

Authors:  Naushad Ali; Heba Allam; Randal May; Sripathi M Sureban; Michael S Bronze; Ted Bader; Shahid Umar; Srikant Anant; Courtney W Houchen
Journal:  J Virol       Date:  2011-09-21       Impact factor: 5.103

2.  Humanized murine model for HBV and HCV using human induced pluripotent stem cells.

Authors:  Xiao-Ling Zhou; Gareth J Sullivan; Pingnan Sun; In-Hyun Park
Journal:  Arch Pharm Res       Date:  2012-02-28       Impact factor: 4.946

3.  CCL18/PITPNM3 enhances migration, invasion, and EMT through the NF-κB signaling pathway in hepatocellular carcinoma.

Authors:  Zeyu Lin; Wenbin Li; Heyun Zhang; Wei Wu; Yaorong Peng; Yunjie Zeng; Yunle Wan; Jie Wang; Nengtai Ouyang
Journal:  Tumour Biol       Date:  2015-10-08

4.  Hepatocellular Carcinoma Occurs at an Earlier Age in Africans, Particularly in Association With Chronic Hepatitis B.

Authors:  Ju Dong Yang; Adam Gyedu; Mary Yeboah Afihene; Babatunde M Duduyemi; Eileen Micah; T Peter Kingham; Mulinda Nyirenda; Adwoa Agyei Nkansah; Salome Bandoh; Mary J Duguru; Edith N Okeke; Marie-Jeanne Kouakou-Lohoues; Abdelmounem Abdo; Yaw Asante Awuku; Akande Oladimeji Ajayi; Abidemi Emmanuel Omonisi; Ponsiano Ocama; Abraham O Malu; Shettima Mustapha; Uchenna Okonkwo; Mbang Kooffreh-Ada; Jose D Debes; Charles Onyekwere; Francis Ekere; Igetei Rufina; Lewis R Roberts
Journal:  Am J Gastroenterol       Date:  2015-11       Impact factor: 10.864

5.  Efficacy and safety of transarterial radioembolization versus chemoembolization in patients with hepatocellular carcinoma.

Authors:  Laura E Moreno-Luna; Ju Dong Yang; William Sanchez; Ricardo Paz-Fumagalli; Denise M Harnois; Teresa A Mettler; Denise N Gansen; Piet C de Groen; Konstantinos N Lazaridis; K V Narayanan Menon; Nicholas F Larusso; Steven R Alberts; Gregory J Gores; Chad J Fleming; Seth W Slettedahl; William S Harmsen; Terry M Therneau; Gregory A Wiseman; James C Andrews; Lewis R Roberts
Journal:  Cardiovasc Intervent Radiol       Date:  2012-10-24       Impact factor: 2.740

6.  Identification and characterization of a novel small-molecule inhibitor of β-catenin signaling.

Authors:  Evan R Delgado; Jing Yang; Juhoon So; Stephanie Leimgruber; Michael Kahn; Tohru Ishitani; Donghun Shin; Gabriela Mustata Wilson; Satdarshan P Monga
Journal:  Am J Pathol       Date:  2014-05-10       Impact factor: 4.307

Review 7.  APSA Awardee Submission: Tumor/cancer stem cell marker doublecortin-like kinase 1 in liver diseases.

Authors:  Charles B Nguyen; Courtney W Houchen; Naushad Ali
Journal:  Exp Biol Med (Maywood)       Date:  2016-10-04

8.  Impact of country of birth on age at the time of diagnosis of hepatocellular carcinoma in the United States.

Authors:  Ju Dong Yang; Sean F Altekruse; Mindie H Nguyen; Gregory J Gores; Lewis R Roberts
Journal:  Cancer       Date:  2016-08-29       Impact factor: 6.860

9.  Diabetes Mellitus Heightens the Risk of Hepatocellular Carcinoma Except in Patients With Hepatitis C Cirrhosis.

Authors:  Ju Dong Yang; Hager Amed Mohamed; Jessica L Cvinar; Gregory J Gores; Lewis R Roberts; W Ray Kim
Journal:  Am J Gastroenterol       Date:  2016-08-16       Impact factor: 10.864

10.  LncRNA WWOX-AS1 sponges miR-20b-5p in hepatocellular carcinoma and represses its progression by upregulating WWOX.

Authors:  Dafeng Xu; Xiangmei Liu; Jincai Wu; Yu Wang; Kailun Zhou; Wenmei Chen; Jiacheng Chen; Cheng Chen; Liang Chen
Journal:  Cancer Biol Ther       Date:  2020-09-15       Impact factor: 4.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.